Table 1.
Demographic profile and baseline clinical characteristics of the ITP patients who received eltrombopag
| Variable | Median (range) or n (%) |
|---|---|
| Evaluable pateints | 53 |
| Females | 23 (43.4%) |
| Age (years) | 35 (17-78) |
| Interval from ITP diagnosis to Eltrombopag | 2.06 year (32 days-14.227 year) |
| Number of prior therapies | 3 (1-8) |
| One line | 1 (1.89%) |
| Two lines | 12 (22.64%) |
| Three lines | 14 (26.41%) |
| Four lines | 12 (22.64%) |
| Five lines | 5 (9.43%) |
| Six lines | 2 (3.77%) |
| Seven lines | 3 (5.66%) |
| Eight lines | 2 (3.77%) |
| Different therpaies received prior to Eltrombopag | |
| Corticosteroids | 51 (96.23%) |
| Intravenous Immunoglobulin (IVIg) | 24 (45.28%) |
| Anti-RhD Immunoglobulin | 9 (16.98%) |
| Splenectomy | 8 (15.09%) |
| Rituximab | 16 (30.19%) |
| Dapsone | 44 (83.02%) |
| Danazol | 23 (43.39%) |
| Azathioprine | 18 (33.96%) |
| Vincristine | 5 (9.43%) |
| Hemoglobin (g/dL) | 12.9 (6.9-17.1) |
| WBC (/μL) | 8000 (4200-19900) |
| Platelet count (/μL) | 10000 (1000-30000) |